Does SARS-Cov-2 invade the brain? Translational lessons from animal models

S Natoli, V Oliveira, P Calabresi, L F Maia, A Pisani, S Natoli, V Oliveira, P Calabresi, L F Maia, A Pisani

Abstract

The current coronavirus disease (COVID-19) outbreak, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has raised the possibility of potential neurotropic properties of this virus. Indeed, neurological sequelae of SARS-CoV-2 infection have already been reported and highlight the relevance of considering the neurological impact of coronavirus (CoV) from a translational perspective. Animal models of SARS and Middle East respiratory syndrome, caused by structurally similar CoVs during the 2002 and 2012 epidemics, have provided valuable data on nervous system involvement by CoVs and the potential for central nervous system spread of SARS-CoV-2. One key finding that may unify these pathogens is that all require angiotensin-converting enzyme 2 as a cell entry receptor. The CoV spike glycoprotein, by which SARS-CoV-2 binds to cell membranes, binds angiotensin-converting enzyme 2 with a higher affinity compared with SARS-CoV. The expression of this receptor in neurons and endothelial cells hints that SARS-CoV-2 may have higher neuroinvasive potential compared with previous CoVs. However, it remains to be determined how such invasiveness might contribute to respiratory failure or cause direct neurological damage. Both direct and indirect mechanisms may be of relevance. Clinical heterogeneity potentially driven by differential host immune-mediated responses will require extensive investigation. Development of disease models to anticipate emerging neurological complications and to explore mechanisms of direct or immune-mediated pathogenicity in the short and medium term is therefore of great importance. In this brief review, we describe the current knowledge from models of previous CoV infections and discuss their potential relevance to COVID-19.

Keywords: COVID-19; SARS-CoV-2; animal models; coronavirus; neurotropism; systematic review; viral infections.

Conflict of interest statement

The authors declare no financial or other conflicts of interest that relate to the research covered in this article.

© 2020 European Academy of Neurology.

References

    1. World Health Organization ‐ Coronavirus disease (COVID‐2019) situation reports. 2020. (accessed 19/04/2020)
    1. World Health Organization ‐ MERS‐CoV. Disease outbreak news. 2019. (accessed 08/04/2020)
    1. World Health Organization . Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Based on data as of the 31 December 2003. (accessed 03/04/2020)
    1. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID‐19‐associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020. 10.1148/radiol.2020201187
    1. Mao L, Jin H, Wang M, et al. Neurological manifestations of hospitalized patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020.10.1001/jamaneurol.2020.1127
    1. Callaway E. Labs rush to study coronavirus in transgenic animals — some are in short supply. Nature 2020; 579: 183–183.
    1. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953–1966.
    1. Hung ECW, Chim SSC, Chan PKS, et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. Clin Chem 2003; 49: 2107–2108.
    1. Lau K, Yu W, Chu C, Lau S, Sheng B. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis 2004; 10: 342–344.
    1. Ding Y, He L, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: Implications for pathogenesis virus transmission pathways. J Pathol 2004; 203: 622–630.
    1. Li W, Moore MJ, Vasilieva N, et al. Angiotensin‐converting enzyme 2: a functional receptor for SARS coronavirus. Nature 2003; 426: 450–454.
    1. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631–637.
    1. Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin‐angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 292: 373–381.
    1. McCray PB, Pewe L, Wohlford‐Lenane C, et al. Lethal infection of K18‐hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol 2007; 81: 813–821.
    1. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol 2008; 82: 7264–7275.
    1. Desforges M, Le Coupanec A, Stodola JK, Meessen‐Pinard M, Talbot PJ. Human coronaviruses: Viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res 2014; 194: 145–158.
    1. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005; 202: 415–424.
    1. Spiegel M. Interaction of severe acute respiratory syndrome‐associated coronavirus with dendritic cells. J Gen Virol 2006; 87: 1953–1960.
    1. Subbarao K, Roberts A. Is there an ideal animal model for SARS? Trends Microbiol 2006; 14: 299–303.
    1. Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol 2015; 13: 123–129.
    1. Gong S‐R, Bao L‐L. The battle against SARS and MERS coronaviruses: reservoirs and animal models. Anim Model Exp Med 2018; 1: 125–133.
    1. Glass WG, Subbarao K, Murphy B, Murphy PM. Mechanisms of host defense following severe acute respiratory syndrome‐coronavirus (SARS‐CoV) pulmonary infection of mice. J Immunol 2004; 173: 4030–4039.
    1. Hogan RJ, Gao G, Rowe T, et al. Resolution of primary severe acute respiratory syndrome‐associated coronavirus infection requires Stat1. J Virol 2004; 78: 11416–11421.
    1. Arabi YM, Harthi A, Hussein J, et al. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS‐CoV). Infection 2015; 43: 495–501.
    1. Kim JE, Heo JH, Kim HO, et al. Neurological complications during treatment of middle east respiratory syndrome. J Clin Neurol 2017; 13: 227–233.
    1. Chan RWY, Chan MCW, Agnihothram S, et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol 2013; 87: 6604–6614.
    1. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus‐EMC. Nature 2013; 495: 251–254.
    1. Al‐Badri G, Leggio GM, Musumeci G, Marzagalli R, Drago F, Castorina A. Tackling dipeptidyl peptidase IV in neurological disorders. Neural Regen Res 2018; 13: 26–34.
    1. Wang N, Shi X, Jiang L, et al. Structure of MERS‐CoV spike receptor‐binding domain complexed with human receptor DPP4. Cell Res 2013; 23: 986–993.
    1. Agrawal AS, Garron T, Tao X, et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 2015; 89: 3659–3670.
    1. Hao X, Lv Q, Li F, Xu Y, Gao H. The characteristics of hDPP4 transgenic mice subjected to aerosol MERS coronavirus infection via an animal nose‐only exposure device. Anim Model Exp Med 2019; 2: 269–281.
    1. Zhou J, Chu H, Li C, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis. J Infect Dis 2014; 209: 1331–1342.
    1. Baseler L, de Wit E, Feldmann H. A comparative review of animal models of Middle East respiratory syndrome coronavirus infection. Vet Pathol 2016; 53: 521–531.
    1. Vergara‐Alert J, van den Brand JMA, Widagdo W, et al. Livestock susceptibility to infection with Middle East respiratory syndrome coronavirus. Emerg Infect Dis 2017; 23: 232–240.
    1. de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS‐CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci USA 2013; 110: 16598–16603.
    1. Prescott J, Falzarano D, de Wit E, et al. Pathogenicity and viral shedding of MERS‐CoV in immunocompromised rhesus macaques. Front Immuno 2018; 9: 205.
    1. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS‐5734) treatment in the rhesus macaque model of MERS‐CoV infection. Proc Natl Acad Sci USA 2020; 117: 6771–6776.
    1. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain‐Barré syndrome associated with SARS‐CoV‐2 infection: causality or coincidence? Lancet Neurol 2020; 19: 383–384.
    1. Wrapp D, Wang N, Corbett KS, et al. Cryo‐EM structure of the 2019‐nCoV spike in the prefusion conformation. Science 2020; 367: 1260–1263.
    1. Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus‐specific human monoclonal antibody. Emerg Microbes Infect 2020; 9: 382–385.
    1. Glowacka I, Bertram S, Müller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 2011; 85(9): 4122–4134.
    1. Hoffmann M, Kleine‐Weber H, Schroeder S, et al. SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–280.
    1. Brann DH, Tsukahara T, Weinreb C, Logan DW, Datta SR. Non‐neural expression of SARS‐CoV‐2 entry genes in the olfactory system suggests mechanisms underlying COVID‐19‐associated anosmia. BioRxiv. 10.1101/2020.03.25.009084
    1. Shan C, Yao Y‐F, Yang X‐L, et al.Infection with novel coronavirus (SARS‐CoV‐2) causes pneumonia in the rhesus macaques. ResearchSquare. 10.21203/rs.2.25200/v1
    1. Bao L, Deng W, Huang B, et al.The pathogenicity of SARS‐CoV‐2 in hACE2 transgenic mice. BioRxiv. 10.1101/2020.02.07.939389
    1. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS‐CoV2 may be at least partially responsible for the respiratory failure of COVID‐19 patients. J Med Virol 2020; 24–27. 10.1002/jmv.25728
    1. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. Front Cell Neurosci 2018; 12: 386.
    1. Li Y, Fu L, Gonzales DM, Lavi E. Coronavirus neurovirulence correlates with the ability of the virus to induce proinflammatory cytokine signals from astrocytes and microglia. J Virol 2004; 78: 3398–3406.
    1. Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol 2005; 5: 917–927.
    1. Bergmann CC, Lane TE, Stohlman SA. Coronavirus infection of the central nervous system: host‐virus stand‐off. Nat Rev Microbiol 2006; 4: 121–132.
    1. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. J Virol 2000; 74: 8913–8921.
    1. Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. Pediatrics 2004; 113: e73–e76.
    1. Yamashita M, Yamate M, Li GM, Ikuta K. Susceptibility of human and rat neural cell lines to infection by SARS‐coronavirus. Biochem Biophys Res Commun 2005; 334: 79–85.
    1. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002; 532: 107–110.
    1. Chan JF, Chan KH, Choi GK, et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 2013; 207: 1743–1752.
    1. Wagner L, Klemann C, Stephan M, von Horsten S. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins. Clin Exp Immunol 2016; 184: 265–283.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren